PharVision Advisers’s Johnson & Johnson JNJ Stock Holding History

PharVision Advisers’s Portfolio JNJ Stock Details JNJ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,771	Closed	-$367K	–	383
2025 Q4	$367K	Buy	+1,771	New	+$350K	0.19%	157

Other funds holding JNJ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

PharVision Advisers's JNJ Position: Q1 2026 in Review

PharVision Advisers sold out of Johnson & Johnson (JNJ) in Q1 2026, closing a stake of 1,771 shares — an estimated $367K sold.

PharVision Advisers first reported a position in JNJ in Q4 2025 and held it in 1 quarter. The position peaked at $367K in Q4 2025. 4,615 funds tracked by Wall St. Rank hold JNJ as of Q1 2026.

PharVision Advisers reported no remaining Johnson & Johnson position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 1,771 Johnson & Johnson shares in Q1 2026, an estimated $367K.
PharVision Advisers first reported a position in Johnson & Johnson in Q4 2025 and held it in 1 quarter.
PharVision Advisers's Johnson & Johnson position peaked at $367K in Q4 2025.
4,615 funds tracked by Wall St. Rank held Johnson & Johnson as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.